Back to the program

Roundtable

TL26-28 Roundtable Discussions

Thu, Sep 17, 11:45 AM - 1:00 PM Room Timberlawn Bethesda North Marriott Hotel & Conference Center

3 Presentations

TL26: Interpret, Navigate and Plan for FDA Draft Guidance on Overall Survival to Develop Innovative Oncology Medicine

11:45 AM - 1:00 PM

Co-authors: Xiaoling Wu (AZ)

overall survival oncology causal interface treatment switching safety

TL27: Mitigating Confounding from Treatment Switching: Methodology and Policy Implications for OS

11:45 AM - 1:00 PM

Co-authors: Peixin Zhang

overall survival treatment switching confounding Estimand sensitivity analysis

TL28: AI-Enabled Statistical Learning to Identify Optimal Biological Dose in Early-Phase Oncology Trials

11:45 AM - 1:00 PM

Kentaro Takeda (Astellas Pharma Global Development, Inc.)

Co-authors: Annie Wang (Astellas)

AI-enabled methods clinical trial digital twins early-phase oncology optimal biological dose targeted learning

↑